POLE and sarcoma: To further evaluate the therapeutic specificity of targeting POLE in CIC::DUX4 sarcoma cells, we treated NCC_CDS1_X1_C1 and NCC_CDS2_C1 with Aphidicolin, a DNA polymerase inhibitor (no POLE specific inhibitors are commercially available to our knowledge).